Objective: To identify the prognostic significance of TERT promoter mutations (TERTp-mut) and their associations with common molecular alterations in glioblastomas (GBMs).
Recently, mutations affecting the promoter region of the telomerase reverse transcriptase (TERT) gene have been reported in numerous cancers. [1] [2] [3] [4] Gliomas and especially glioblastomas (GBMs) were among the most frequently affected tumors. [4] [5] [6] [7] These mutations occurred in 2 hotspot positions (chr5, 1,295,228 C.T and chr5, 1,295,250 C.T), located 2124 and 2146 base pairs upstream from the ATG start site (2124 G.A and 2146 G.A). 7 Both mutations conferred enhanced TERT promoter activity, possibly by generating a consensus binding site (CCTGAA.CCGGAA) for E-twenty-six transcription factors. 2, 3 The TERT gene codes for a highly specialized reverse transcriptase catalyzing, with other members of the telomerase complex, the 39 extension of chromosome ends by adding hexamers repeats. 8, 9 TERT expression and telomerase activity are usually low in normal tissues, and the constant shortening of telomeres finally leads to cell senescence. In contrast, most human cancers are characterized by an increased activity of telomerase allowing the maintenance of telomere length, thus avoiding induction of senescence and conferring unrestricted growth properties to cancer cells. 10, 11 A number of genetic and genomic alterations have already been described in GBM, including epidermal growth factor receptor (EGFR) amplification, cyclin-dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, methylguanine methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase (IDH) mutation. To date, only MGMT promoter methylation and IDH mutation have been proven to be prognostic in GBMs. 12, 13 In this study, we investigated the prevalence and the prognostic impact of TERT promoter mutations (TERTp-mut), in a series of 395 patients with GBM treated in our department. We then correlated the TERTp-mut status with the other genetic alterations.
METHODS Patients and tissue samples. Selection of patients was based on the following criteria: histologic diagnosis of primary GBM according to the World Health Organization classification, and clinical data and follow-up available in the neurooncology database (Onconeurothèque Paris). We considered primary GBM when the first symptoms appeared less than 3 months before the patient was referred to the clinics. We excluded patients known to have a history of seizure or known low-grade gliomas.
The QIAamp DNA Mini Kit was used to extract tumor DNA from frozen tumors, as described by the manufacturer (Qiagen, Courtaboeuf, France). DNA was extracted from blood samples using a conventional saline method.
For the determination of EGFR amplification, CDKN2A homozygous deletion, and loss of chromosomes 9 and 10, genomic profiling was performed by comparative genomic hybridization array analysis or single nucleotide polymorphism array, as previously described. 14, 15 Mutational status of IDH1, IDH2, and TP53 (tumor protein p53) was determined using the Sanger technique, as previously described. 16 MGMT promoter methylation status was determined by 2-stage nested methylation-specific PCR after bisulfite modification. 17 Standard protocol approvals, registrations, and patient consents. Collection of tumor and blood samples and clinicopathologic information was undertaken with informed consent and relevant ethical board approval in accordance with the tenets of the Declaration of Helsinki.
Determination of TERTp-mut status. The promoter region of the TERT gene was amplified as follows: TERT-F GGCCGATTCGACCTCTCT and TERT-R AGCACCTCGCGGTAGTGG; 3 minutes at 94°C; 35 cycles at 94°C 15 seconds, 60°C 45 seconds, 72°C 1 minute, with a final step at 72°C for 8 minutes. PCR products were then purified with the Agencourt AMPure XP PCR purification protocol (Beckman Coulter, Villepinte, France). Purified PCR products were then sequenced using the Big-Dye Terminator Cycle Sequencing Ready Reaction (PerkinElmer, Villebon sur Yvette, France). Sequences were purified with the Agencourt CleanSEQ protocol according to the manufacturer's instructions (Beckman Coulter) and analyzed on an ABI Prism 3730 DNA Analyzer (Applied Biosystems, Saint Aubin, France).
Statistical analysis. The x 2 test was used to compare the genotypes' distribution. The association with continuous variables was calculated with a Mann-Whitney test.
Overall survival (OS) was defined as the time between the diagnosis and death or last follow-up. Patients who were still alive at the last follow-up were considered as a censored event in analysis. Progression-free survival (PFS) was defined as the time between the diagnosis and recurrence or last follow-up. Patients who were recurrence-free at the last follow-up were considered as a censored event in the analysis. To find clinical and/or genomic factors related to OS (or PFS), survival curves were calculated according to the Kaplan-Meier method, and differences between curves were assessed using the log-rank test. Variables with a significant p value were used to build a multivariate Cox model. Two-sided p values ,0.05 were considered significant.
RESULTS

Somatic and constitutional TERTp-mut status.
A population of 395 primary GBMs was screened for the presence of TERTp-mut. Median age at diagnosis was 58.5 years (range 18.2-89.1). Median Karnofsky Performance Score was 80 (range 20-100). At diagnosis, 281 patients (71.1%) underwent partial or total surgical resection and 114 (28.9%) were biopsied. One hundred seventy-four patients were treated with radiotherapy and temozolomide. One hundred fortyfour patients were treated upfront with radiotherapy alone, either because they were treated before 2005 (122 patients) or because they were older than 70 years (21 patients). Twenty-seven patients received upfront chemotherapy. Fourteen patients did not receive any specific oncology treatment. The information was missing for 36 patients, who have been excluded from all PFS analyses. Median OS was 14.8 months and median PFS was 8.6 months.
We found 299 (75.7%) TERTp-mut, including 222 C228T (74.2%) and 77 C250T (25.8%) mutations. One tumor had both C228T and C250T mutations. This patient was considered as C228T TERT mutant for all subsequent analyses. Patients with TERTp-mut were older than patients with TERT promoter wild type (TERTp-wt) GBMs: median age at diagnosis was 59.6 vs 53.6 years, respectively (p , 0.0001). There was no difference of age at diagnosis between patients harboring C228T and C250T TERT mutations (data not shown).
To confirm that such mutations were all somatic events, we investigated the presence of the TERTp-mut in blood DNA corresponding to 56 TERTp-mut GBMs. No mutation was found in blood DNA (data not shown).
TERTp-mut is an independent factor of poor prognosis in GBM. In patients with GBM, patients with TERTp-mut had significantly shorter OS and PFS than patients with TERTp-wt. Median OS was 13.8 months in patients with TERTp-mut compared to 18.4 months in patients with TERTp-wt (p , 0.0001) (figure 1). Accordingly, PFS was 8.3 and 10.4 months, respectively (p , 0.0001). We did not find any difference in outcome between the C228T and C250T TERTp-mut (figure e-1 on the Neurology ® Web site at Neurology.org).
We then input the following factors as candidate variables in the multivariate Cox proportional hazards regression model analysis: age at diagnosis, IDH mutation, extent of surgery, concomitant and adjuvant chemotherapy, Karnofsky Performance Score, MGMT promoter methylation status, and TERTp-mut. TERTp-mut appeared as an independent prognostic factor for both OS and PFS in GBM (tables 1 and 2).
TERT mutations are associated with specific prognostic and molecular subgroups. The association of TERTp-mut with the other molecular alterations frequently found in GBMs is presented in table 3.
IDH mutation was associated with TERTp-wt GBM (22/88 [25%] vs 8/284 [2.8%] in TERTp-mut GBM). We therefore enquired whether the higher incidence of IDH mutation could explain the better outcome of TERTp-wt patients compared with TERTp-wt GBM. However, stratifying our population according to the TERTp status, we found that TERTp-mut was prognostic in both IDH-wt GBM (OS 5 13.7 vs 17.5 months, p 5 0.006) and IDH-mutation GBM (OS 5 13.8 vs 37.6 months, p 5 0.02). Moreover, it is particularly striking to note that IDH mutation was associated with a better outcome in TERTp-wt GBM (OS 5 37.6 vs 17.5 months, p 5 0.04) but not TERTp-mut GBM (OS 5 13.8 vs 13.7 months, p 5 not significant) (figure 2).
In contrast to IDH mutation, EGFR amplification, present in 144 GBMs, was associated with TERTpmut GBM (131/299 [43.8%] vs 13/96 [13.5%] in TERTp-wt GBM). We found that EGFR amplification had no prognostic impact per se (figure e-2). However, when stratifying according to TERTp status, we found that EGFR amplification was associated with shorter OS and PFS in the TERTp-wt group (OS 5 13.3 vs To better understand this paradox, we compared the age of these different populations: there was no significant difference of age in the EGFR amplified group between TERTp-mut patients (59.1 years) and TERTp-wt patients (55.7 years) (p 5 0.5), whereas TERTp-mut patients were significantly older than TERTp-wt patients (60 vs 49 years, p , 0.0001) in the EGFR nonamplified group. We therefore analyzed the impact of the TERTp-mut according to age in the EGFR-wt group. The results, reported in figure e-3, show that in each age category (,50 years; 50-65 years; .65 years), patients with TERTp-wt had a longer survival, but this was particularly relevant in the group of patients younger than 50 years. We also found that TERTp-mut were associated with chromosome 10q loss and CDKN2A homozygous deletion, but these associations did not result in a prognostic stratification of our cohort.
Prognostic classification of GBMs based on TERTp, EGFR,
and IDH status. Building on these results, we propose a 4-group molecular classification of GBMs: (1) GBMs with TERTp-mut constituting a homogeneous group (OS 5 13.8 months); (2) GBMs with EGFR amplification and TERTp-wt (OS 5 13.3 months), all of which are IDH-wt; (3) IDH mutation having no prognostic impact in this group; and (4) EGFR-wt and TERTp-wt, characterized by a much better prognosis particularly in the presence of the IDH mutation (OS 5 37.6 months), but even in the absence of the IDH mutation (26.5 months) (figure 4). DISCUSSION TERT is the most frequently mutated gene in GBMs, 4, 6, 7 suggesting that it may be an early event in the development of these tumors. These mutations create a putative binding site for the E-twenty-six/ternary complex factor transcription factors and increase 2-to 4-fold transcriptional activity of the promoter. 3, 18 Increasing telomerase activity confers a selective advantage and promotes immortalization of cells by preventing the senescence induced by telomere shortening.
In our series, TERTp-mut were associated with an older age at diagnosis, as previously reported in medulloblastomas, 7 conjunctival melanomas, 1 and recently in gliomas. 19 Telomeres are shorter in the GBMs of older patients, 20 and preventing telomere shortening may therefore be more critical in older patients. Accordingly, the polymorphism rs2736100, which maps to the TERT locus, has also been associated with the IDH-wt and older age gliomas. 21 In this work, we show that TERTp-mut is an independent factor of poor outcome in GBMs. Indeed, we clearly show here that this effect is not due to the association of IDH mutation with TERTp-wt status as previously believed. 22 Moreover, the impact of TERTp-mut is even stronger in patients with IDH mutation than in patients with IDH-wt, with a median OS decreasing from 37.6 months in TERTp-wt to 13.8 months in TERTp-mut. In other words, our data suggest that the favorable prognostic impact of the IDH mutation in GBMs is lost in the presence of an associated TERT mutation, because the survival in IDH mutation TERTp-mut GBMs is identical to standard (i.e., IDH-wt) GBMs.
We further dissected the prognostic impact of the TERTp-mut in the context of different genetic backgrounds. EGFR amplification is a hallmark of GBM. It affects 40% of GBMs and is mutually exclusive with IDH mutation. In line with previous reports, we show here that EGFR amplification has no prognostic impact in the whole GBM population. 23, 24 However, determination of the TERTp-mut status revealed that in the TERTp-wt group, patients with EGFR-wt had a median survival twice superior to that of patients with EGFR amplification. Consequently, we show a very sharp and opposite effect of the TERTp-mut on survival according to EGFR status. Similar results have been obtained in medulloblastomas, also showing an opposite prognostic effect of TERTp-mut according to different genetic subtypes. 25 Our study also makes it clear that the difference of age-a well-known prognostic factor in GBM-is not a valid explanation, because in the EGFR amplified subgroup, patients with TERTpmut were older but still had a better outcome (OS 5 15.8 vs 13.3 months, p 5 0.05).
Finally, we propose a 4-group molecular classification that summarizes our results: when either EGFR amplification or TERTp-mut is present, the prognosis is poor with median survival ranging from 12 to 16 months. Median survival is much better when none of these 2 alterations is present, ranging from more than 2 years for patients with IDH-wt, to more than 3 years for patients with IDH mutation.
In this study, we found that the TERTp-mut is a strong and independent prognostic marker in GBM, and is not related to IDH status. We also show an opposite prognostic effect of TERTp-mut in EGFRwt GBM. Finally, we propose a refined prognostic classification of GBMs based on the joint analyses of TERT, EGFR, and IDH.
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